Sun Pharmaceutical Industries Limited (SUNPHARMA) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹1,904.5 (-0.55% day change)
Key ratios
- P/E ratio
- 39.84
- P/B ratio
- 5.05
- ROE (%)
- 13.74
- ROCE (%)
- 15.73
- Debt/Equity
- 0.06
- Dividend yield (%)
- 0.93
- Market cap (₹ Cr)
- 456,953.35
Forensic checks
Piotroski F-Score: 5/9 · Altman Z-Score: 12.18 · Beneish M-Score: -2.45
InvestSights quality score
72.4/100 — Above Average (descriptive data-driven composite; not a recommendation)
Latest earnings call (Q2 FY27)
AI summary: The central signal is a widening divergence between strong domestic execution and softer near-term momentum in the US innovative franchise. India delivered ₹55,523 million of sales, up 17.3%, with management attributing 50%-60% of growth to volume and new products. By contrast, US sales declined 8.2% because of lenalidomide erosion, while Ilumya’s slowdown reflected both…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.